Amarin to Ring NASDAQ Closing Bell
October 31, 2011 16:00 ET | Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 31, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...
Amarin Announces NDA Submission for AMR101 for the Treatment of Patients With Very High Triglycerides
September 26, 2011 04:00 ET | Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 26, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...
Amarin to Present at the UBS Global Life Sciences Conference
September 19, 2011 07:00 ET | Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...
Amarin Announces Successful MARINE Phase 3 Clinical Trial Results Published in The American Journal of Cardiology
September 01, 2011 04:00 ET | Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...
Data From Amarin's AMR101 Phase 3 MARINE Trial to be Presented at the European Society of Cardiology (ESC) Congress 2011
August 25, 2011 08:00 ET | Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 25, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...
Amarin to Present at the Wedbush Securities Life Sciences Management Access Conference
August 12, 2011 14:42 ET | Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 12, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...
Amarin Announces Agreement From FDA on Special Protocol Assessment for AMR101 Outcomes Study
August 10, 2011 04:00 ET | Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, Ireland, Aug. 10, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today...
Amarin Reports Second Quarter 2011 Results
August 09, 2011 17:00 ET | Amarin Corporation plc
- Company on Track for NDA Filing This Quarter - - Conference Call Set for 8:00 am EDT August 10 - MYSTIC, Conn. and DUBLIN, Aug. 9, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc...
Amarin to Present at the 2011 Canaccord Genuity Growth Conference
August 08, 2011 07:05 ET | Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, Aug. 8, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that...
Amarin Announces Q2, 2011 Results Conference Call
August 08, 2011 07:00 ET | Amarin Corporation plc
MYSTIC, Conn. and DUBLIN, Aug. 8, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, has scheduled a...